

International Research Journal of Modernization in Engineering Technology and Science (Peer-Reviewed, Open Access, Fully Refereed International Journal)

**Impact Factor- 8.187** 

Volume:06/Issue:11/November-2024

www.irjmets.com

# **BRIEF REVIEW ON ORAL SUSPENSION**

## Mr. Akshay B Kakad<sup>\*1</sup>, Adinath Sangale<sup>\*2</sup>, Dr. Megha Salve<sup>\*3</sup>

<sup>\*1,2</sup>Shivajirao Pawar College of Pharmacy, Pachegaon, Maharashtra, India.

<sup>\*3</sup>Department of Pharmacy, Pachegaon, Maharashtra, India.

DOI: https://www.doi.org/10.56726/IRJMETS63771

## ABSTRACT

This review evaluates oral control suspensions' efficacy, safety and pharmacokinetics. Key findings show therapeutic effects, manageable side effects and favorable pharmacokinetic profiles. Healthcare professionals should consider dosage guidelines, potential interactions and patient- specific factors.

Keywords: Oral Control Suspension, Efficacy, Safety, Pharmacokinetics, Disease Management.

# I. INTODUCTION

An oral control suspension is a liquid pharmaceutical formulation designed to release the active ingredient(s) at a controlled rate, maintaining therapeutic drug concentrations over an extended period.

## > Indications for Oral Control Suspension

Oral control suspensions are prescribed for various medical conditions, including:

## A) Infectious Diseases

- 1. Bacterial infections (e.g., pneumonia, sinusitis)
- 2. Fungal infections (e.g., oral thrush, candidiasis)
- 3. Viral infections (e.g., HIV, herpes)

## B) Inflammatory Conditions

- 1. Rheumatoid arthritis
- 2. Osteoarthritis
- 3. Asthma
- 4. Allergic reactions.
- C) Gastrointestinal Disorders
- 1. Gastroesophageal reflux disease (GERD)
- 2. Peptic ulcers
- 3. Irritable bowel syndrome (IBS)
- 4. Inflammatory bowel disease (IBD)

## D) Chronic Diseases

- 1. Diabetes mellitus
- 2. Hypertension
- 3. Hyperlipidemia
- 4. Chronic obstructive pulmonary disease (COPD)

## E) Pediatric Indications

- 1. Ear infections (otitis media)
- 2. Respiratory tract infections
- 3. Gastrointestinal infections

## F) Other Indications

- 1. Pain management
- 2. Anxiety disorders
- 3. Seizure disorders.
- 4. Migraines. (2)



#### International Research Journal of Modernization in Engineering Technology and Science (Peer-Reviewed, Open Access, Fully Refereed International Journal)

Volume:06/Issue:11/November-2024 Impact Factor- 8.187 ww

## www.irjmets.com

### > Active Ingredients in Oral Control Suspensions

Oral control suspensions contain various active ingredients, including:

### A) Antibiotics

- 1. Amoxicillin
- 2. Ciprofloxacin
- 3. Clarithromycin
- 4. Metronidazole

### B) Anti-inflammatory Agents

- 1. Ibuprofen
- 2. Naproxen
- 3. Prednisone
- 4. Celecoxib

### C) Antifungal Agents

- 1. Fluconazole
- 2. Itraconazole
- 3. Ketoconazole
- 4. Voriconazole

## D) Antiviral Agents

- 1. Acyclovir
- 2. Valacyclovir
- 3. Zidovudine
- 4. Lamivudine

## E) Antacids/Anti-ulcer Agents

- 1. Ranitidine
- 2. Omeprazole
- 3. Lansoprazole
- 4. Famotidine

## F) Pain Management

- 1. Acetaminophen
- 2. Tramadol
- 3. Codeine
- 4. Hydrocodone

## G) Other Therapeutic Agents

- 1. Metformin (diabetes)
- 2. Atenolol (hypertension)
- 3. Albuterol (asthma)
- 4. Ondansetron (antiemetic)

### H) Combination Products

- 1. Amoxicillin-clavulanate
- 2. Ibuprofen-acetaminophen
- 3. Clarithromycin-amoxicillin

### > Dosage Forms of Oral Control Suspension

Oral control suspensions are available in various dosage forms:

### A) Liquid Dosage Forms

1. Suspensions: Uniform mixture of active ingredients and excipients.



International Research Journal of Modernization in Engineering Technology and Science (Peer-Reviewed, Open Access, Fully Refereed International Journal)

Volume:06/Issue:11/November-2024Impact Factor- 8.187www.irjmets.com

- 2. Emulsions: Mixture of two or more immiscible liquids.
- 3. Solutions: Homogeneous mixture of dissolved substances.



#### Figure 1: Liquid Oral Dosage form

#### B) Semi-Solid Dosage Forms

- 1. Gels: Semi-solid suspension of active ingredients.
- 2. Pastilles: Soft, chewable dosage form.

#### C) Solid Dosage Forms with Liquid Components

- 1. Effervescent tablets: Tablets dissolving in water.
- 2. Dispersible tablets: Tablets dispersing in liquid.
- D) Specialized Dosage Forms
- 1. Extended-release suspensions: Prolonged release.
- 2. Delayed-release suspensions: Release after specific time.
- 3. Controlled-release suspensions: Predictable release rate.
- E) Pediatric and Geriatric Dosage Forms
- 1. Pediatric drops: Concentrated liquid formulations.
- 2. Geriatric suspensions: Easy-to-swallow formulations. (8)

## II. EFFICACY

Oral control suspension reviews highlight their efficacy in improving patient compliance, reducingside effects and enhancing bioavailability. These suspensions allow for flexible dosing and ease of swallowing, making them ideal for pediatric and geriatric patients or those with difficulty tolerating solid dosage forms.

> Key Benefits:

**Improved Patient Compliance:** Oral control suspensions promote adherence to treatment regimens due to their ease of administration and palatability.

**Reduced Side Effects:** Sustained-release formulations minimize adverse reactions by maintaining optimal drug concentrations.

Enhanced Bioavailability: Oral suspensions facilitate rapid absorption, boosting therapeutic efficacy.

> Therapeutic Applications:

Infectious Diseases: Effective against bacterial, fungal and viral infections.

Inflammatory Conditions: Manages rheumatoid arthritis, osteoarthritis and asthma.

**Gastrointestinal Disorders:** Treats gastroesophageal reflux disease (GERD), peptic ulcers and irritable bowel syndrome (IBS)

> Formulation Advantages:

Sustained Release: Maintains therapeutic drug levels over extended periods.

Taste Masking: Ion exchange resins and nanosponges effectively mask bitter tastes.

Stability: Dry syrup and reconstitutable suspensions ensure chemical stability. (3,4,5)



International Research Journal of Modernization in Engineering Technology and Science (Peer-Reviewed, Open Access, Fully Refereed International Journal)

Volume:06/Issue:11/November-2024 Impact Factor- 8.187

www.irjmets.com

### III. SAFETY

Oral control suspensions have been found to be safe and effective, improving patient compliance, reducing side effects and enhancing bioavailability. They're particularly beneficial for pediatric and geriatric patients or those who have difficulty tolerating solid dosage forms.

#### > Key Safety Considerations

**Reduced Side Effects**: Oral control suspensions minimize adverse reactions by maintaining optimal drug concentrations.

Improved Bioavailability: These suspensions facilitate rapid absorption, boosting therapeutic efficacy.

**Patient Compliance:** The ease of administration and palatability of oral control suspensions promote adherence to treatment regimens.

Stability: Reconstitutable oral systems demonstrate adequate chemical stability of the drug duringshelf life.

#### > Formulation Advantages

Sustained Release: Oral control suspensions maintain therapeutic drug levels over extended periods.

Taste Masking: Ion exchange resins and nanosponges effectively mask bitter tastes.

**Gastroretention:** Gastroretentive drug delivery systems increase stomach residence duration for site-specific drug release. (6)

## **IV. PHARMACOKINETICS**

Pharmacokinetics of oral control suspensions involve the study of how these formulations are absorbed, distributed, metabolized and excreted by the body. This process is crucial in determining the efficacy and safety of oral control suspensions.

#### > Key Pharmacokinetic Parameters

**Absorption:** Oral control suspensions are designed to facilitate rapid absorption, ensuring optimal bioavailability.

**Distribution**: The active ingredients are distributed throughout the body, reaching targeted sites.**Metabolism**: Hepatic metabolism plays a significant role in transforming the active ingredients.**Excretion**: The metabolites are eliminated through renal or fecal excretion.

> Factors Influencing Pharmacokinetics Solubility: Affects absorption rates and bioavailability.

Permeability: Influences absorption across biological membranes.

**pH: Impacts** solubility and absorption.

Food Effects: May alter absorption rates.

## V. DOSAGE AND ADMINISTRATION

#### **Dosage and Administration of Oral Control Suspension**

Oral control suspensions require careful dosage and administration to ensure optimal efficacy and safety.

- Dosage Considerations
- 1. Initial Dosage: Determined by patient's age, weight and medical condition.
- 2. Maintenance Dosage: Adjusted based on patient response and therapeutic monitoring.
- 3. Maximum Dosage: Should not exceed recommended limits.
- Administration Guidelines
- 1. Shake Well: Before administration to ensure uniform suspension.
- 2. Accurate Measurement: Use provided measuring devices.
- 3. Administration Time: Follow recommended schedule.
- 4. Food and Liquid Intake: Consider potential interactions.
- > Special Populations
- 1. Pediatric Patients: Adjust dosage according to age and weight.
- 2. Geriatric Patients: Monitor for increased sensitivity.
- **3. Renal/Hepatic Impairment:** Adjust dosage based on clearance.



#### International Research Journal of Modernization in Engineering Technology and Science (Peer-Reviewed, Open Access, Fully Refereed International Journal)

Volume:06/Issue:11/November-2024Impact Factor- 8.187www.irjmets.com

- Potential Interactions
- 1. Drug-Drug Interactions: Monitor for synergistic or antagonistic effects.
- 2. Drug-Food Interactions: Consider nutritional impacts.
- 3. Drug-Disease Interactions: Be aware of condition-specific considerations.
- Monitoring and Adjustment.
- 1. Therapeutic Levels: Monitor drug concentrations.
- 2. Adverse Reactions: Adjust dosage or discontinue if necessary.
- 3. Patient Compliance: Encourage adherence to prescribed regimen. (7)

### VI. INTERACTIONS

Oral control suspensions can interact with various substances, affecting their efficacy and safety.

- > Drug-Drug Interactions
- **1. Antacids:** Interfere with absorption.
- 2. Antibiotics: May interact with oral control suspension's antibacterial properties.
- 3. Anticoagulants: Monitor for increased bleeding risk.
- 4. Anti-inflammatory agents: Potential for additive effects.
- Drug-Food Interactions
- 1. Dairy Products: Calcium can reduce absorption.
- 2. Grapefruit Juice: Inhibits metabolism.
- 3. High-Fat Meals: Affect absorption rates.
- Drug-Disease Interactions
- 1. Renal Impairment: Adjust dosage based on clearance.
- 2. Hepatic Impairment: Monitor for increased sensitivity.
- 3. Gastrointestinal Disorders: Potential for altered absorption.
- > Other Interactions
- 1. Alcohol: Avoid concurrent use.
- 2. Herbal Supplements: Potential for pharmacokinetic interactions.
- 3. Vitamins and Minerals: Interactions may alter efficacy.
- > Contraindications
- 1. Hypersensitivity: Avoid use in patients with known allergies.
- 2. Pregnancy and Lactation: Use only when benefits outweigh risks.
- Precautions
- 1. Monitoring: Regularly check therapeutic levels and adverse reactions.
- 2. Dose Adjustment: Based on patient response and interactions. (1,2,9)

## VII. STORAGE AND HANDLING

Storage and Handling of Oral Control Suspension

Oral control suspensions require proper storage and handling to maintain their efficacy, safety and stability.

- > Storage Conditions
- **1. Temperature:** 15-30°C (59-86°F).
- 2. Humidity: 50-70%.
- 3. Lighting: Protect from direct sunlight.
- **4. Container:** Tight, light-resistant and child-resistant.
- Handling Precautions
- 1. Shake Well: Before administration.
- 2. Cleanliness: Maintain cleanliness during handling.



### International Research Journal of Modernization in Engineering Technology and Science (Peer-Reviewed, Open Access, Fully Refereed International Journal)

 Volume:06/Issue:11/November-2024
 Impact Factor- 8.187
 www.irjmets.com

- **3. Contamination:** Avoid contamination.
- **4. Expiration Date:** Check before use.
- Stability Considerations
- 1. Chemical Stability: Ensure stability during shelf life.
- 2. Physical Stability: Prevent settling or aggregation.
- 3. Microbiological Stability: Prevent microbial growth.
- Transportation Guidelines
- 1. Temperature Control: Maintain recommended temperatures.
- 2. Security: Prevent damage or theft.
- 3. Labeling: Clear labeling and instructions.
- Patient Counseling
- 1. Storage Instructions: Educate patients.
- 2. Handling Precautions: Inform patients.
- 3. Expiration Date: Advise patients to check. (1,2)

## VIII. PATIENT INFORMATION

Oral control suspensions are designed to improve patient compliance, reduce side effects and enhance bioavailability. These suspensions are particularly beneficial for pediatric and geriatric patients or those who have difficulty tolerating solid dosage forms.

> Key Benefits for Patients

**Improved Patient Compliance:** Easy administration and palatability promote adherence to treatment regimens.

**Reduced Side Effects:** Sustained-release formulations minimize adverse reactions.

Enhanced Bioavailability: Rapid absorption boosts therapeutic efficacy. (10)

Ideal Characteristics of Oral Control Suspensions Uniform dispersion of solid drug particles in a vehicle.
Flexible dosage administration and easy to swallow. Minimum drug accumulation in the body.

Better utilization of the drug. Reduction in fluctuation of drug levels.

### Patient Counseling

Store suspensions at 15-30°C (59-86°F) and protect from direct sunlight. Shake well before administration.

Check expiration dates.

Inform patients about potential interactions with other medication.

## > Therapeutic Applications

Infectious diseases. Inflammatory conditions. Gastrointestinal disorders.

## IX. CONCLUSION

Oral control suspensions offer a versatile and efficacious treatment option, enhancing patient outcomes through improved compliance, reduced side effects and optimized bioavailability. Theseformulations have demonstrated safety, efficacy and stability in various therapeutic applications.

## X. REFERENCE

- [1] "Pharmaceutics: The Science of Dosage Form Design" by M. E. Aulton (ChurchillLivingstone, 2013)
- [2] "Remington: The Science and Practice of Pharmacy" by A. R. Gennaro (Lippincott Williams & Wilkins, 2012)
- [3] Aulton, M. E. (2013). Pharmaceutics: The Science of Dosage Form Design. ChurchillLivingstone.
- [4] Gennaro, A. R. (2012). Remington: The Science and Practice of Pharmacy. Lippincott Williams & Wilkins.
- [5] Desai, K. G. H. (2015). Pharmaceutical Dosage Forms and Drug Delivery Systems. CRCPress.
- [6] "Pharmaceutical Dosage Forms and Drug Delivery Systems" by K. G. H. Desai (CRCPress, 2015)



International Research Journal of Modernization in Engineering Technology and Science (Peer-Reviewed, Open Access, Fully Refereed International Journal) Volume:06/Issue:11/November-2024 Impact Factor- 8.187 www.irjmets.com

[7] Oral Controlled Release Formulations: Design, Development and Evaluation" by H.Chen (Wiley, 2010)

[8] "Pharmaceutical Dosage Forms and Drug Delivery Systems" by K. G. H. Desai (CRC Press, 2015)

- [9] "Controlled Release in Oral Drug Delivery" by C. G. Wilson and P. J. Crowley (Springer, 2011).
- [10] https://www.researchgate.net/publication/353412308\_A\_REVIEW\_ON\_DUAL\_RELEA SE\_ORAL\_RECONSTITUTABLE\_SUSPENSION\_World\_Journal\_of\_Pharmaceutical\_Research.